A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 485-490

  Kondo, Ken ^a   Sakamoto, Junichi ^b   Nakazato, Hiroaki ^c   Koike, Akihiko ^d   Kitoh, Tsuyoshi ^e   Hachisuka, Kitao ^f   Saji, Shigetoyo ^g   Yura, Jiro ^h   Nimura, Yuji ⁱ   Hamajima, Nobuyuki ^e   Katoh, Kenichi ^c   Yamaguchi, Akihiro ^f   Miya, Ki Ichi ^g   Yamauchi, Masaji ^j   Mizuno, Isamu ^h   Nagino, Masato ⁱ   Takagi, Hiroshi ⁱ  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b Center for Disabled Children   (Japan)

^c Yokoyama Gastrointestinal Hospital   (Japan)

^d Aichi College of Medicine   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f OGAKI MUNICIPAL HOSPITAL   (Japan)

^g GIFU UNIVERSITY   (Japan)

^h NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

ⁱ NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

more..

Author keywords

5 Fluorouracil; 5 deoxy 5 fluorouridine; Chemotherapy; Fluorinated pyrimidines; Gastric cancer; Oral chemotherapy; Phase III study; Randomized study; Supportive therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXIFLURIDINE; FLOXURIDINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTESTINE TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR; SURVIVAL; TIME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0034183297     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.485     Document Type: Review

References (18)

1. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ and Wieand HS: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053-1057, 1986.
2. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H: Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
3. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LMG, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA and Baron MG: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751-754, 1991.
4. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter T and Duez N: An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4: 1799-1803, 1986.
5. Wakui A: Phase II trial of 5′-deoxy-5-fluorouridine in the treatment of gastric cancer: a multicentre cooperative study. J Int Med Res 16 (Suppl 2): 17B-18B, 1988.
6. Fujimoto S, Akao T, Itoh, Koshizuka I, Koyano K, Kitsukawa Y, Takahashi M, Minami T, Ishigami H, Miyazaki M, Amamiya K, Ohyama Y, Ono K, Kure M, Itoh K and Hikosaka T: Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Ann Surg 185: 462-466, 1977.
7. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H, Akiya T, Hamada T and Kiyohashi A: A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72: 658-662, 1993.
8. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71: 112-123, 1980.
9. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K and Akiyama S: Angiogenic activity of enzymes. Nature 368: 198, 1994.
10. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy 5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31: 175-178, 1983.
11. Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H and Yagi Y: Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann 71: 190-196, 1980.
12. Armstrong RD and Codman E: 5′-deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res 43: 2525-2528, 1983.
13. Uehara N, Baba H, Nitta K, Kunimoto T, Takeuchi M, Sasaki T and Tanaka T: The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors. Jpn J Cancer Res (Gann) 76: 1034-1041, 1985.
14. Taguchi T: Survival and changes of clinical laboratory data in phase II study with 5′-DFUR. Jpn J Cancer Chemother 23: 1019-1029, 1996.
15. Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T and Ishitsuka H: Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50: 4528-4532, 1990.
16. Yasue M, Sakamoto J, Morimoto T, Yasui K, Kuno N, Kurimoto K, Teramukai S and Ohashi Y: Evaluation of the effect of pancreatic resection in advanced pancreatic cancer with special reference using hospital-free survival as a measure of quality of life. Jpn J Clin Oncol 25: 37-45, 1995.
17. Burris HA III, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
18. Gelber DR and Goldhirsch A: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772-1779, 1986.